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aBsTRacT
INTRODUCTION: The research programme Safeguarding the 
Brains of our smallest Children (SafeBoosC) aims to test the 
benefits and harms of cerebral near-infrared spectroscopy 
(NIRS) oximetry in infants born before 28 weeks of gesta-
tion. In a phase II trial, infants will be randomised to visible 
cerebral NIRS oximetry with pre-specified treatment guide-
lines compared to standard care with blinded NIRS-monitor-
ing. The primary outcome is duration multiplied with the 
extent outside the normal range of regional tissue oxygen 
saturation of haemoglobin (rStO2) of 55 to 85% in percent-
age hours (burden). This study was a pilot of the Visible 
 Oximetry Group.
MATERIAL AND METHODS: This was an observational study 
including ten infants. 
RESULTS: The median gestational age was 26 weeks + three 
days, and the median start-up time was 133 minutes after 
delivery. The median recording time was 69.7 hours, mean 
rStO2 was 64.2 ± 4.5%, median burden of hyper- and hy-
poxia was 30.3% hours (range 2.8-112.3). Clinical staff re-
sponded to an out of range value 29 times – only once to 
values above 85%. In comparison, there were 83 periods of 
more than ten minutes with an rStO2 below 55% and four 
episodes with an rStO2 above 85%. These periods accounted 
for 72% of the total hypoxia burden. A total of 18 of the 29 
interventions were adjustments of FiO2 which in 13 of the 
18 times resulted in an out-of-range SpO2. Two infants suf-
fered second-degree burns from the sensor. Five infants 
died. In all cases, this was unrelated to NIRS monitoring and 
treatment.
CONCLUSION: The intervention of early cerebral NIRS moni-
toring proved feasible, but prolonged periods of hypoxia 
went untreated. Thus, a revision of the treatment guideline 
and an alarm system is required. 
FUNDING: The Elsass Foundation funded the present study.
TRIAL REGISTRATION: Clinicaltrials.gov: NCT01530360.
An extremely preterm infant born before 28 weeks of 
gestation has about 25% risk of surviving with a severe 
neurodevelopmental deficit [1]. A likely risk factor is 
fluctuating cerebral blood flow during the transitional 
phase in the first days of life [2, 3]. The regional tissue 
oxygen saturation of haemoglobin (rStO2) can be esti-
mated in a non-invasive and continuous manner by 
near-infrared spectroscopy (NIRS) [4]. rStO2 is primarily 
correlated with venous saturation [5, 6] – and hence 
with the balance between cerebral oxygen delivery and 
oxygen consumption, and is an estimate of cerebral 
blood flow. SafeBoosC is a research programme aiming 
to test the benefits and harms of cerebral NIRS oximetry 
in extremely preterm infants [4, 7]. 
The research programme Safeguarding the Brains  
of our smallest Children (SafeBoosC) phase II trial hy-
pothesizes that the burden of cerebral hypo- and hyper-
oxia can be reduced by 50% with the further aim to re-
duce brain injury. Infants will be randomised to cerebral 
NIRS oximetry during the first 72 hours of life and a spe-
cific treatment guideline versus blinded NIRS monitoring 
and standard care. The present study was an observa-
tional pilot including ten infants in the experimental 
group.
maTERial and mEThOds
study design
This was the SafeBoosC pilot study of the experimental 
arm of the SafeBoosC phase II focusing on the initial 14 
days of the planned trial period. It was approved by the 
local ethics committee (J. no. H-2-2011-069) and con-
ducted at the Copenhagen University Hospital, Rigshos-
pitalet, Denmark. Written informed consent was ob-
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tained from the parents of each child before or shortly 
after delivery. The study was funded by a grant from the 
Elsass Foundation. 
Patients
Infants born between 24 weeks 0 days of gestation and 
27 weeks 6 days of gestation were eligible for enrolment 
within three hours after birth. An a priori decision not to 
provide life support was an exclusion criterion.
Enrolment and treatment
Infants were enrolled from September though Decem-
ber 2011. Two NIRS oximeters were used, the INVOS 
5100C (Covidien, Boulder, CO, USA) with the Adult 
 SomaSensor and the NONIN EQUANOX 7600 (NONIN, 
Plymouth, MN, USA) with the 8000CA sensor model. 
NIRS monitoring was initiated within three hours of 
birth and maintained until 72 hours of age. The sensor 
was repositioned every 4-6 hours to avoid skin burns. 
safeBoosc clinical guidelines
rStO2 is a composite measure of tissue oxygen saturation 
across arterial, capillary and venous beds and reflects a 
balance between cerebral oxygen delivery (CDO2) and 
cerebral metabolic rate (CMRO2). In preterm infants, 
CMRO2 is unlikely to vary much, and a change in rStO2 
largely reflects changes in CDO2. The factors that influ-
ence CDO2 are arterial oxygen saturation, haemoglobin 
concentration and cerebral blood flow. The treatment 
guideline is thus focused on interventions that alter one 
or more of these parameters, e.g. an increase in PaCO2 
and thus a decrease of the vascular resistance in the 
brain and an increase in cerebral blood flow. The full 
treatment guideline can be downloaded at the Safe-
BoosC website [8].
normal ranges
The target range of rStO2 in this SafeBoosC pilot was 55-
85%. The range was established from unpublished data of 
NIRS monitoring of 390 infants admitted to the neonatal 
department in the Wilhelmina Hospital, Utrecht. The 
range represents the mean rStO2 ± 2 standard deviations 
(SD) and was collected with INVOS with the Adult Soma-
Sensor. The hypoxic–ischaemic threshold of rStO2 in pre-
term infants is unknown, but data from piglets suggest 
that it is probably below 50% [9, 10]. The effect of hyper-
oxia on neurodevelopmental outcome is debated, but to 
avoid values above mean + 2 SD seems reasonable. 
interventions 
The treatment of the infants was at the discretion of the 
attending medical staff. The research team was not  
involved. The sensor was only to be moved according  
to the planned repositioning and not based on rStO2  
values. 
assessment
The nurses documented any interventions motivated by 
an out of range rStO2 reading. If available, mean arterial 
pressure (MABP), arterial haemoglobin oxygen satura-
tion (SpO2), and transcutaneus partial pressure of CO2 
were collected at the time of intervention, 30 and 60 
minutes afterwards, however, at one and four hours for 
blood transfusion and treatment of a patent ductus ar-
teriosus. Death before discharge and serious adverse 
events were recorded. All infants were examined with 
cerebral ultrasound within the first three days and again 
at 14 days to detect cerebral injury. 
The NIRS data were sampled at approximately 0.2 
Hz with INVOS and 0.25 Hz with NONIN.
statistical analysis
Mean rStO2 and SD of the monitoring period for each 
 infant were calculated. The time with rStO2 below 55% 
and above 85% was multiplied by the extent of deviation 
to provide an estimate of the burden of hypoxia and 
 hyperoxia in %-hours. Normality was tested with Sharp-
iro-Wilk. The agreement of rStO2 before and after repo-
sitioning of the sensor was estimated [11]. The one-hour 
effect of each intervention on rStO2 was tested by the 
paired t test. Statistical testing was done with Analyst-
Soft Inc., StatPlus:mac LE, Version 2009.
Trial registration: Clinicaltrials.gov: NCT01530360.
REsUlTs
Ten infants (six girls) were enrolled with a median gesta-
tional age of 26 weeks and three days (range 24 + 0 to 
27 + 3 weeks + days) and a mean birth weight of 816 
grams. Antenatal steroids were administered to all 
mothers. Six of the ten neonates were delivered by 
 Caesarean section.
cerebral near-infrared spectroscopy data
Cerebral NIRS monitoring was started 133 minutes 
(range 42-178 minutes) after delivery. The median re-
Extremely preterm infant.
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cording time was 69.7 hours (range 67.2-71.2 hours). 
96% of the possible data points were recorded. The 
within subject rStO2 was normally distributed (p = 0.9). 
There was no difference in mean rStO2 between the 
three days (Table 1). The mean rStO2 of the seven in-
fants monitored with INVOS was 62.3 ± 3.3% versus 68.3 
± 4.0% of the three infants monitored with NONIN  
(p = 0.03). The mean difference of rStO2 before and after 
sensor repositioning was 1.3% with limits of agreement 
of –16.6 to +19.3% (Figure 1). 
Burden of hypo- and hyperoxia
The median burden of hypo- and hyperoxia was 30.3%- 
hours (Table 2). The median burden of hyper- and hypox-
ia was 37.7%-hours (range 2.8-112.3%-hours) with INVOS 
and 8.5%-hours (range 2.4-18.4%-hours) with NONIN. 
Treatment interventions
The staff responded to an out-of-range value 29 times. 
In comparison, there were 83 periods of more than ten 
consecutive minutes with an rStO2 below 55% and four 
episodes with an rStO2 above 85%. The median duration 
was 13 minutes. These periods accounted for 72% of the 
total burden of hypoxia. The longest period was 168 
minutes. Only once did the NONIN go below 55% for 
more than ten minutes, while INVOS never gave values 
over 85% for ten minutes. 
In 15 of the 18 times that the FiO2 was increased, 
the rStO2 was increased 60 minutes afterwards (p = 
0.01). Unfortunately, the SpO2 was above the local tar-
get range for SpO2 of 85-92% 13 of the 15 times. 
Dopamine was initiated five times. This was not as-
sociated with significant increases in rStO2 60 minutes 
afterwards (p = 0.1). Positive end-expiratory pressure 
was increased, reduced and respiratory frequency de-
creased once, respectively. One fluid bolus was given 
and positive inspiratory pressure was reduced twice. 
clinical data
Five of the ten infants died (four to 33 days of age). 
Three died from necrotising enterocolitis (NEC), one 
from a catheter-related complication and one from 
 hypoxic respiratory failure. No major cerebral haemor-
rhages were found. Seven of the ten infants were me-
chanically ventilated at some point during the first 72 
hours, seven received surfactant and seven received 
prophylactic indomethacin.
adverse events
Two infants suffered a burn from the INVOS sensor. One 
burn evolved into a 4 × 4-mm keloid process. In the sec-
ond case, the infant died ten days old with a still visible 
mark on the forehead. There are no data to suggest that 
NIRS can damage tissue below the skin. In one instance, 
the tracheal tube disconnected from the ventilator dur-
ing repositioning of the sensor. Moreover, once the 
 sensor was positioned upside down while still showing 
rStO2 values of about 45%. 
The infant was otherwise stable and the attending 
clinician chose to contact the research team and the 
mistake was corrected. The incident did not affect the 
treatment of the infant. 
TaBlE 1
Within subject mean rStO2 ± standard deviation, % 64.2 ± 4.5
Within subject standard deviation, % 6.8
Mean rStO2 of day 1 ± standard deviation, % 64.6 ± 3.8
Mean rStO2 of day 2 ± standard deviation, % 64.9 ±4.9
Mean rStO2 of day 3 ± standard deviation, % 63.1 ± 6.0
Regional tissue oxygen saturation of haemoglobin (rStO2) characteristics.
FigURE 1
Bland-Altman plot of agreement between rStO2 before and after sensor repositioning. The upper and 
lower lines represent the 95% limits of agreement. The middle line represents the mean difference. 
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TaBlE 2
Regional tissue oxygen saturation of haemoglobin (rStO2) spent outside 
55-85%. The values are median (range).
Time out of range, hours 7.7 (0.5-19.6)
Time below 55%, hours 6.9 (0.2-19.6)
Time above 85%, hours 0.0 (0-1.3)
Burden of hypoxia, rStO2  < 55%, %-hoursa 30.2 (1.0-112.3)
Burden of hyperoxia, rStO2  > 85%, %-hoursa 0.1 (0-7.6)
Total burden of hyper- and hypoxia, %-hoursa 30.3 (2.4-112.3)
a) %-hours is the multiplication of duration and extent out of range.
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case story
A 24-week infant was treated with dopamin to keep the 
MABP above the “gestational age limit” of 24 mmHg 
during the first days of life. As dopamin was stopped, 
the blood pressure dropped to possibly acceptable lev-
els of 24-25 mmHg, but rStO2 decreased to an rStO2 of 
15%. When dopamin was restarted, MABP increased to 
26-27 mmHg and the rStO2 normalised. 
alarm limits
Two alarm systems with potential to improve timely in-
tervention were explored post-hoc. A “time-alarm”: ten 
minutes with rStO2 below 55% and a “burden-alarm”: 
25% minutes below during last ten minutes. The “time-
alarm” would have alerted during 49% of the total bur-
den of hypoxia, while the “burden-alarm” would have 
alerted during 77% (Figure 2). 
discUssiOn
SafeBoosC is, to our knowledge, the first trial in extre-
mely preterm infants to test the benefit of treatment 
guided by cerebral NIRS oximetry. This pilot study shows 
that it was feasible to begin NIRS monitoring within 
three hours after birth and during the first 72 hours of 
life in extremely preterm infants in an NICU that had no 
prior experience with clinical NIRS monitoring. However, 
we identified potential problems regarding appropriate 
application of sensors as well as appropriate response to 
out-of-range values.
The complex intervention of NIRS and the treat-
ment guideline will affect the totality of clinical manage-
ment of infants depending on various external factors, 
such as level of experience with NIRS at the specific 
NICU, local guidelines for treatment of low blood pres-
sure and local SpO2 ranges. We therefore assumed that 
a qualitative study could prove valuable for the final 
planning of the SafeBoosC phase II trial [12]. 
Our approach has limitations. The study was con-
ducted in one institution only which limits generalisabil-
ity. Data collection was left to the nursing staff and re-
duced to a single value at the time of intervention and 
twice afterwards. This is insufficient to analyse the ef-
fects of interventions in detail. Thirdly, when staff re-
cords the effects of interventions, it is potentially biased. 
The overall mean rStO2 was 64.2 ± 4.5%. Previously, 
an rStO2 of 67-68% in the first three first days of life in 
infants born before a gestational age 32+0 has been re-
ported [13]. Difference in gestational age could be the 
explanation. Our data indicate a systematic bias be-
tween the NONIN and the INVOS with the used sensors. 
A systematic comparison with paired measurements on 
preterm infants should be performed to validate this. 
The wide limits of agreement between measurements 
before and after repositioning (Figure 1) are as expected 
from the literature [13-18]. The upcoming phase II trial 
will examine the possibility of reducing the burden of 
cerebral hypo- and hyperoxia. This goal is reachable with 
NIRS oximeters as long as these are qualitatively accu-
rate. Studying clinical benefit in terms of survival with-
out neurodevelopmental deficit, a phase III trial will, 
however, depend on the quantitative accuracy of indi-
vidual oximeters as well as the appropriateness of the 
intervention thresholds. 
The choice of %-hours as primary outcome in the 
phase II trial is not evidence-based. It is intuitive that 
both the extent and the duration of hypoxia matter, but 
their impact on brain injury may not be linear. 
However,%-hours is the simplest form and is likely to be 
a relevant marker for the effect of interventions. Data 
from the phase-II study will be analysed to provide fur-
ther insight into the association between rStO2 and brain 
injury in preterm infants. 
As expected, an increasing FiO2 increased the rStO2. 
Unfortunately, the increased FiO2 often resulted in an 
out-of-range SpO2. Large randomised trials have shown 
that even a five percentage point difference in SpO2 tar-
get range affects the mortality rate [19, 20]. Thus, a 
change in the trial treatment guideline is warranted. The 
case story illustrates a steep drop in rStO2 and presuma-
bly cerebral blood flow after cessation of a low-dose do-
pamin infusion. The 50 percentage point fall in rStO2 
with a fall in MABP of 5-10 mmHg exceeds what would 
be expected even with complete absence of cerebral 
FigURE 2
The accumulated burden of hypoxia during the study period in a single patient. The upper plot shows 
the whole period with the trial interventions (  ). Middle plot shows the “time-alarm” ( ) and lower 
plot the “burden-alarm” ( ) during selected four hours. The alarms alert until the specific conditions 
are no longer met.
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 autoregulation. However, the normalisation of rStO2 
when dopamin was started again suggests that a clinical-
ly important decrease in CBF did occur. The case illus-
trates the potential value of this form of “individualised 
medicine”, i.e. to adapt treatment to the responses in 
the individual patient.
Our results point to a less than perfect implementa-
tion of the treatment guideline. Time limits for interven-
tion were not specified for the staff and it is possible 
that the clinical judgement was that most episodes out 
of range would resolve spontaneously. Moreover, the 
rStO2 did not show on central monitoring, i.e. the nurses 
had to be present at the bedside to recognise the low 
values. Finally, the poor reproducibility of rStO2, the lack 
of a well-documented hypoxic-ischaemic threshold and 
the large spontaneous variation of rStO2 may have 
caused the attending staff to disregard the rStO2 if all 
other clinical data looked fine. 
To intervene every time a highly fluctuating rStO2 
goes below 55% may possibly lead to overtreatment. 
However, the “time-alarm” would be insufficient for the 
phase II trial only alerting during 49% of the total burden 
of hypoxia, whereas the “burden-alarm” would alert 
during 77% of the total hypoxic burden. 
With 700 hours of monitoring, the adverse event 
rate was reasonable. Side effects of cerebral oximetry 
are important to acknowledge. For the upcoming phase 
II trial, adverse events will become a challenge. The con-
trol group likely suffers the same expected risks as the 
experimental group and a higher drop-out rate in the 
control group might be expected if adverse events are 
not kept to an absolute minimum. Thus, careful instruc-
tions to the attending staff are needed. 
Three cases of NEC was more than expected from 
the unit-specific incidence of 6% in neonates weighing 
less than 1,500 g. Case reviews did not point to a link be-
tween cerebral oximetry or the interventions made and 
the complications leading to death in any of the cases. 
The mortality is therefore considered to have occurred 
by random in this high-risk population. Even so, the ob-
served mortality points to the need for close trial moni-
toring of the phase II trial.
The SafeBoosC project begs ethical considerations. 
The adverse device effects appear tolerable, but inter-
vention to change physiological parameters within nor-
mal ranges is a new approach. Similarly, physiological 
parameters outside the normal range may be left un-
treated if the cerebral oxygenation is normal. However, 
many of the thresholds that normally guide treatment of 
these infants are not evidence-based, e.g. thresholds for 
blood pressure. Cerebral oxygenation is a highly relevant 
physiological parameter and oximeters have already 
been approved for clinical use. Diagnostic and monitor-
ing techniques are usually brought into clinical care 
without proper trials. We may have a narrow window of 
opportunity for such a trial. 
cOnclUsiOn
The intervention of the SafeBoosC phase II trial is feasi-
ble. However, this pilot study identified issues concern-
ing the NIRS instruments, the treatment guideline and 
the local implementation that need to be considered in 
order to ensure optimal execution of the trial interven-
tion. 
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